Zejula Archives -

GSK takes fight to AZ/Merck & Co with first-line ovarian cancer approval

https://pharmaphorum.com/news/fda-approves-gsks-zejula/

GSK starts 2020 on a high, but warns of tougher times ahead

https://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/

PARP & DNA Damage Response Inhibitors Summit 2020

https://pharmaphorum.com/events/parp-dna-damage-response-inhibitors-summit-2020/

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer

https://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/

Tesaro stock rockets as rumours of Roche takeover abound

https://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/

Search